Clinical Trial

Alzheimer's Disease Neuroimaging Initiative 4

Study acronym: ADNI4
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.
Protocol Amendment History 1 change
notable Trial sites expanded: 62 -> 65 locations 2026-08-15
Trial Details
NCT Number NCT05617014
Lead Sponsor University of Southern California
Collaborators: Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Conditions Mild Cognitive Impairment, Alzheimer Disease, Dementia
Enrollment 1,500 participants
Start Date 2023-06-09
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14